1. New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
- Author
-
Moore, Donald C., Peery, Matthew R., Tobon, Katherine A., Raheem, Farah, Hwang, Grace S., Alhennawi, Lin, and Hughes, Mitchell E.
- Subjects
THERAPEUTIC use of antineoplastic agents ,DRUG approval ,DRUG efficacy ,HOSPITAL emergency services ,CANCER chemotherapy ,B cell lymphoma ,ANTINEOPLASTIC agents ,PLATINUM ,SALVAGE therapy ,HEMATOPOIETIC stem cell transplantation ,IMMUNOTHERAPY ,PATIENT safety - Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common form of aggressive non-Hodgkin lymphoma. Approximately 40% of patients with DLBCL will experience disease relapse or will be refractory to first line chemoimmunotherapy, necessitating second-line salvage therapy. This has historically consisted of platinum-based chemotherapy regimens followed by autologous hematopoietic stem cell transplantation with curative intent for transplant-eligible patients or palliative chemotherapy for transplant-ineligible patients. In recent years there have been several new therapeutic agents approved for the treatment of relapsed/refractory DLBCL, thereby expanding the therapeutic landscape. These agents include polatuzumab vedotin, tafasitamab, loncastuximab tesirine, selinexor, and anti-CD19 chimeric antigen receptor T-cell therapies such as axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel. This review summarizes the pharmacology, efficacy, safety, dosing, and administration of new agents recently approved for the treatment of relapsed/refractory DLBCL. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF